Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 43, Issue 11, 2002, Pages 2145-2149

  Nabhan, C ^a   Peterson, L A ^a   Kent, S A ^a   Tallman, M S ^a   Dewald, G ^b   Multani, P ^c   Gordon, L I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c BIOGEN   (United States)

Author keywords

Acute myelogenous leukemia; MLL gene rearrangement; Radioimmunotherapy; Secondary leukemia; Zevalin

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; ETOPOSIDE; GYRASE INHIBITOR; IBRITUMOMAB TIUXETAN; LOMUSTINE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; TENIPOSIDE; TOSITUMOMAB I 131; VINCRISTINE; ANTIBODY CONJUGATE; CD20 ANTIGEN; DNA BINDING PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN; TRANSCRIPTION FACTOR; YTTRIUM;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CHROMOSOME 11Q; CHROMOSOME ANALYSIS; CYTOPENIA; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TARGETING; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; ISOTOPE LABELING; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SIDE EFFECT; CHROMOSOME 11; GENETICS; IMMUNOLOGY; NONHODGKIN LYMPHOMA; PATHOLOGY; PROTO ONCOGENE; RADIATION EXPOSURE; SECOND CANCER;

AGED; AGED, 80 AND OVER; ANTIGENS, CD20; CHROMOSOMES, HUMAN, PAIR 11; DNA-BINDING PROTEINS; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASMS, SECOND PRIMARY; PROTO-ONCOGENES; RADIOIMMUNOTHERAPY; TRANSCRIPTION FACTORS; YTTRIUM RADIOISOTOPES;

EID: 0036838233     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819021000032971     Document Type: Article

References (25)

1. Nadler, L.M., Ritz, J., Hardy, R., Pesando, J.M., Schlossman, S.F. and Stashenko, P. (1981) "A unique cell surface antigen identifying lymphoid malignancies of B cell origin", J. Clin. Investig. 67, 134-140.
2. Miller, R.A., Maloney, D.G., Warnke, R. and Levy, R. (1982) "Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody", N. Engl. J. Med. 306, 517-522.
3. Reff, M.E., Carnier, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. and Anderson, DR. (1994) "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", Blood 83, 435-445.
4. Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A. and Levy, R. (1994) "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma", Blood 84, 2457-2466.
5. Maloney, D., Smith, B. and Appelbaum, F. (1996) "The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma. (NHL) cell lines abstract", Blood 84, 2535a.
6. Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N. and Bonavida, B. (1997) "Chimeric anti-CD20 (IDEC-C2138) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs", Cancer Biother. Radiopharm. 12, 177-186.
7. Shan, D., Ledbetter, J.A. and Press, O.W. (1998) "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies", Blood 91, 1644-1652.
8. Gansow, O.A., Brechbiel, M.W., Mirzadeh, S., Colcher, D. and Roselli, M. (1990) "Chelates and antibodies: current methods and new directions", Cancer Treat. Res. 51, 153-171.
9. Gordon, L., White, C. and Witzig, T. (1999) "Zevalin (IDEC-Y2B8) radioinummotherapy of rituximab refractory follicular non-Hodgkin's lymphoma (NHL): Interim Results", Blood 94, 396a, abstract.
10. Witzig, T., White, C. and Gordon, L. (1999) "Prospective, randomized controlled study of Zevalin (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results (abstract)", Blood 94, 631a.
11. Witzig, T.E., White, C.A., Wiseman, G.A., Gordon, L.I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R.J., Spies, S., Silverman, D.H., Parker, E. and Grillo-Lopez, A.J. (1999) "Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma", J. Clin. Oncol. 17, 3793-3803.
12. Smith, RG. and Doll, R. (1976) "Late effects of x irradiation in patients treated for metropathia haemorrhagica", Br. J. Radiol. 49, 224-232.
13. Vose, J.M., Wahl, R.L., Saleh, M., Robatiner, A.Z., Knox, S.J., Radford, J.A., Zelenetz, A.D., Tidmarsh, G.F., Stagg, R.J. and Kaminski, M.S. (2000) "Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas", J Clin. Oncol. 18, 1316-1323.
14. Kaminski, M., Zelenetz, A. and Press, O. (1998) "Multi-center phase III study of Iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL) (abstract)", Blood 92, 1296a.
15. Kaminski, M.S., Estes, J., Zasadny, K.R., Francis, I.R., Ross, C.W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., Stagg, R., Tidmarsh, G. and Wahl, R.L. (2000) "Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", Blood 96, 1259-1266.
16. Press, O., Eary, J. and Liu, S. (1998) "A phase I/II trial of high-dose iodine 131 anti-B1 (anti-CD20) monoclonal antibody, etoposide, cyclophosphomide, and autologous stem-cell transplantation for patients with relapsed B-cell lymphomas", Proc. Am. Soc. Clin. Oncol. 17, 19a, abstract.
17. Press, O.W. (1999) "Radiolabeled antibody therapy of B-cell lymphomas", Semin. Oncol. 26, 58-65.
18. Thirman, M.J. and Larson, R.A. (1996) "Therapy-related myeloid leukemia", Hematol. Oncol. Clin. N. Am. 10, 293-320.
19. Leone, G., Mele, L., Pulsoni, A., Equitani, F. and Pagano, L. (1999) "The incidence of secondary leukemias", Haematologica 84, 937-945.
20. Super, H.J., McCabe, N.R., Thirman, M.J., Larson, R.A., Le Beau, M.M., Pedersen-Bjergaard, J., Philip, P., Diaz, M.O. and Rowley, J.D. (1993) "Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II", Blood 82, 3705-3711.
21. Hunger, S.P., Tkachuk, D.C., Amylon, M.D., Link, M.P., Carroll, A.J., Welborn, J.L., Willman, C.L. and Cleary, M.L. (1993) "HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities", Blood 81, 3197-3203.
22. Starostik, P., Greiner, A., Schultz, A., Zettl, A., Peters, K., Rosenwald, A., Kolve, M. and Muller-Hermelink, H.K. (2000) "Genetic aberrations common in gastric high-grade large B-cell lymphoma", Blood 95, 1180-1187.
23. Zhu, Y., Monni, O., Franssila, K., Elonen, E., Vilpo, J., Joensuu, H. and Knuutila, S. (2000) "Deletions at 11q23 in different lymphoma subtypes", Haematologica 85, 908-912.
24. Cuneo, A., Bigord, R., Rigolin, G.M., Roberti, M.G., Milani, R., Bardi, A., Minotto, C., Agostini, R, De Angeli, C., Narducci, M.G., Sabbioni, S., Russo, G., Negrini, M. and Castoldi, G. (2000) "Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin's lymphoma: correlation with clinicobiologic features", J. Clin. Oncol. 18, 2607-2614.
25. Taylor, H.J., Gravett, P. and Plowman, P.N. (2000) "Secondary acute myeloblastic leukaemia (AML) (expressing 11q23 mutation) occurring 11 months after chemotherapy/radiotherapy for paediatric non-Hodgkin lymphoma (NHL)", Clin. Oncol. 12, 112-114.